Enzo Biochem Statistics
Total Valuation
Enzo Biochem has a market cap or net worth of $56.09 million. The enterprise value is $6.19 million.
| Market Cap | 56.09M |
| Enterprise Value | 6.19M |
Important Dates
The last earnings date was Thursday, June 13, 2024, after market close.
| Earnings Date | Jun 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Enzo Biochem has 51.46 million shares outstanding. The number of shares has increased by 3.71% in one year.
| Shares Outstanding | 51.46M |
| Shares Change (YoY) | +3.71% |
| Shares Change (QoQ) | +1.43% |
| Owned by Insiders (%) | 24.08% |
| Owned by Institutions (%) | 37.35% |
| Float | 39.58M |
Valuation Ratios
The trailing PE ratio is 1.18.
| PE Ratio | 1.18 |
| Forward PE | n/a |
| PS Ratio | 11.88 |
| Forward PS | n/a |
| PB Ratio | 0.81 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.14 |
| EV / Sales | 1.31 |
| EV / EBITDA | 0.14 |
| EV / EBIT | 0.14 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.50, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.50 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | n/a |
| Interest Coverage | -31.44 |
Financial Efficiency
Return on equity (ROE) is 61.20% and return on invested capital (ROIC) is 5.37%.
| Return on Equity (ROE) | 61.20% |
| Return on Assets (ROA) | 42.50% |
| Return on Capital (ROIC) | 5.37% |
| Revenue Per Employee | $26,374 |
| Profits Per Employee | $249,905 |
| Employee Count | 179 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.08% in the last 52 weeks. The beta is 0.78, so Enzo Biochem's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -41.08% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 45.50 |
| Average Volume (20 Days) | 138,143 |
Short Selling Information
The latest short interest is 560,452, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 560,452 |
| Short Previous Month | 603,572 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.42% |
| Short Ratio (days to cover) | 4.78 |
Income Statement
In the last 12 months, Enzo Biochem had revenue of $4.72 million and earned $44.73 million in profits. Earnings per share was $0.92.
| Revenue | 4.72M |
| Gross Profit | 16.48M |
| Operating Income | 4.10M |
| Pretax Income | 44.73M |
| Net Income | 44.73M |
| EBITDA | 44.83M |
| EBIT | 43.35M |
| Earnings Per Share (EPS) | $0.92 |
Balance Sheet
The company has $57.16 million in cash and $7.26 million in debt, giving a net cash position of $49.90 million or $0.97 per share.
| Cash & Cash Equivalents | 57.16M |
| Total Debt | 7.26M |
| Net Cash | 49.90M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 69.03M |
| Book Value Per Share | 1.34 |
| Working Capital | 54.07M |
Cash Flow
In the last 12 months, operating cash flow was -$42.21 million and capital expenditures -$995,000, giving a free cash flow of -$43.20 million.
| Operating Cash Flow | -42.21M |
| Capital Expenditures | -995,000 |
| Free Cash Flow | -43.20M |
| FCF Per Share | -$0.84 |
Margins
Gross margin is 348.99%, with operating and profit margins of 86.78% and 947.53%.
| Gross Margin | 348.99% |
| Operating Margin | 86.78% |
| Pretax Margin | 947.53% |
| Profit Margin | 947.53% |
| EBITDA Margin | 949.67% |
| EBIT Margin | 918.32% |
| FCF Margin | -915.06% |
Dividends & Yields
Enzo Biochem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.71% |
| Shareholder Yield | -3.71% |
| Earnings Yield | 79.75% |
| FCF Yield | -77.02% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 21, 2004. It was a forward split with a ratio of 105:100.
| Last Split Date | Oct 21, 2004 |
| Split Type | Forward |
| Split Ratio | 105:100 |
Scores
Enzo Biochem has an Altman Z-Score of -0.56 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.56 |
| Piotroski F-Score | 6 |